CXCR2 and prostate carcinoma: CXCR2 expression is upregulated in a number of tumor types, including prostate cancer, colorectal cancer (CRC), and non–small-cell lung cancer (NSCLC) [3–5], and expression of CXCR2 and its ligands is associated with poor patient prognosis [4, 5].